Date: Tue, 2 Jul 2002 09:45:41 -0700 (PDT) From: <thejournal@excite.com> To: <questions@freebsd.org> Subject: The Investment Journal: Biotech Holdings Ltd. Message-ID: <52F8B3D6.000000013.4A3B.9B83.C9C33FE204B7@I9yyCDnW.com>
index | next in thread | raw e-mail
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> <!-- saved from url=(0060)file://X:\Email\Biotech\Docs\The%20Investment%20Journal2.htm --> <html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40">; <head> <meta http-equiv=Content-Type content="text/html; charset=windows-1252"> <meta name=ProgId content=Word.Document> <meta name=Generator content="Microsoft Word 9"> <meta name=Originator content="Microsoft Word 9"> <link rel=File-List href="./The%20Investment%20Journal3_files/filelist.xml"> <title>The Investment Journal</title> <style> <!-- /* Font Definitions */ @font-face {font-family:"Arial Unicode MS"; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:128; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1 -369098753 63 0 4129023 0;} @font-face {font-family:Algerian; panose-1:4 2 7 5 4 10 2 6 7 2; mso-font-charset:0; mso-generic-font-family:decorative; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"Calisto MT"; panose-1:2 4 6 3 5 5 5 3 3 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"Franklin Gothic Demi"; panose-1:2 11 7 3 2 1 2 2 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:647 0 0 0 159 0;} @font-face {font-family:"\@Arial Unicode MS"; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:auto; mso-font-signature:0 0 0 0 0 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; color:windowtext;} h1 {mso-style-next:Normal; margin:0in; margin-bottom:.0001pt; text-align:justify; mso-pagination:widow-orphan; mso-outline-level:1; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; color:windowtext; mso-font-kerning:0pt; font-weight:bold;} h2 {mso-style-next:Normal; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; mso-outline-level:2; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; color:windowtext; font-weight:bold;} h3 {mso-style-next:Normal; margin:0in; margin-bottom:.0001pt; text-align:center; mso-pagination:widow-orphan; mso-outline-level:3; font-size:36.0pt; mso-bidi-font-size:12.0pt; font-family:Algerian; mso-fareast-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman"; color:green; font-weight:bold;} h5 {mso-style-next:Normal; margin:0in; margin-bottom:.0001pt; text-align:center; mso-pagination:widow-orphan; mso-outline-level:5; font-size:14.0pt; mso-bidi-font-size:12.0pt; font-family:Arial; mso-fareast-font-family:"Arial Unicode MS"; color:windowtext; mso-ansi-language:EN-GB; font-weight:bold; mso-bidi-font-weight:normal;} p.MsoHeader, li.MsoHeader, div.MsoHeader {margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; tab-stops:center 3.0in right 6.0in; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; color:windowtext;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText {margin:0in; margin-bottom:.0001pt; text-align:center; mso-pagination:widow-orphan; border:none; mso-border-alt:solid windowtext .5pt; padding:0in; mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt; font-size:36.0pt; mso-bidi-font-size:12.0pt; font-family:Algerian; mso-fareast-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman"; color:green; font-weight:bold;} p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2 {margin:0in; margin-bottom:.0001pt; text-align:center; mso-pagination:widow-orphan; font-size:9.0pt; mso-bidi-font-size:12.0pt; font-family:Arial; mso-fareast-font-family:"Times New Roman"; color:windowtext;} a:link, span.MsoHyperlink {color:blue; text-decoration:underline; text-underline:single;} a:visited, span.MsoHyperlinkFollowed {color:purple; text-decoration:underline; text-underline:single;} p {margin-right:0in; mso-margin-top-alt:auto; mso-margin-bottom-alt:auto; margin-left:0in; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Arial Unicode MS"; color:white;} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} --> </style> </head> <body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'> <div class=Section1> <div align=center> <table border=0 cellspacing=0 cellpadding=0 width=591 bgcolor="#e5d68d" style='width:443.45pt;margin-left:.45in;background:#E5D68D;border-collapse: collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt;background-position-x:0%; background-position-y:50%'> <tr style='height:77.25pt'> <td width=591 nowrap valign=top style='width:443.45pt;padding:0in 5.4pt 0in 5.4pt; height:77.25pt'> <h3>The Investment </h3> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Franklin Gothic Demi"; color:black'>Issue 26<span style="mso-spacerun: yes"> </span></span><b><span style='font-size:36.0pt;mso-bidi-font-size:12.0pt; font-family:Algerian;color:green'>Journal<span style="mso-spacerun: yes"> </span></span></b><span style='font-size:10.0pt;mso-bidi-font-size:12.0pt; font-family:"Franklin Gothic Demi";color:black'>June 2002</span><b><span style='font-size:36.0pt;mso-bidi-font-size:12.0pt;font-family:Algerian; color:#999999'><o:p></o:p></span></b></p> </td> </tr> </table> </div> <p class=MsoNormal align=center style='text-align:center'><span lang=EN-CA style='color:white;mso-ansi-language:EN-CA'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> <p class=MsoHeader align=center style='text-align:center;tab-stops:.5in center 3.0in right 6.0in'><span lang=EN-CA style='font-size:22.0pt;mso-bidi-font-size:12.0pt;font-family:Arial; color:white;mso-ansi-language:EN-CA'><span style="mso-spacerun: yes"> </span></span><span lang=EN-CA style='font-size:22.0pt;mso-bidi-font-size:12.0pt; font-family:Arial;color:green;mso-ansi-language:EN-CA'>BIOTECH HOLDINGS LTD.</span><span lang=EN-CA style='font-size:22.0pt;mso-bidi-font-size:12.0pt;font-family:Arial; color:white;mso-ansi-language:EN-CA'><o:p></o:p></span></p> <p class=MsoHeader style='tab-stops:.5in center 3.0in right 6.0in'><span lang=EN-CA style='mso-ansi-language:EN-CA'> <o:p></o:p></span></p> <table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse; mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr style='height:620.5pt'> <td width=431 valign=top style='width:323.6pt;padding:0in 5.4pt 0in 5.4pt; height:620.5pt'> <table border=0 cellspacing=0 cellpadding=0 bgcolor="#e5d68d" style='background:#E5D68D;border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr> <td width=405 valign=top style='width:303.4pt;padding:0in 5.4pt 0in 5.4pt'> <h1 align=center style='text-align:center'><span style='font-family:"Calisto MT"; color:green'>BIOTECH HOLDINGS PROFILE <o:p></o:p></span></h1> <h1 align=center style='text-align:center'><span style='font-family:"Calisto MT"; color:green'><span style="mso-spacerun: yes"> </span>BREAKTHROUGH DIABETES DRUG</span><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:green'><o:p></o:p></span></h1> </td> </tr> </table> <h1 align=center style='text-align:center'><span style='font-size:10.0pt; font-family:"Calisto MT";mso-bidi-font-family:Arial;color:green'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></h1> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>The Company: Biotech is a pharmaceutical company based in Vancouver, Canada.<span style="mso-spacerun: yes"> </span>Biotech <b>controls and is bringing to market a breakthrough diabetes drug</b>.<span style="mso-spacerun: yes"> </span>The drug, called DIAB II, is classed as an insulin-sensitizing drug. Drugs of this type improve the body’s ability <o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>to make use of insulin, the hormone that controls blood sugar levels.<span style="mso-spacerun: yes"> </span>Currently available insulin-sensitizers such as Avandia and Actos have huge sales volumes<span style="mso-spacerun: yes"> </span>-- <b>over $700 million annually in the case of Avandia, and over $1 Billion for Actos</b><span style="mso-spacerun: yes"> </span>-- despite a number of drawbacks including potential liver toxicity.<span style="mso-spacerun: yes"> </span>The success of these drugs demonstrates the tremendous potential for an effective and safe insulin sensitizer such as DIAB II. </span><span style='font-size:9.0pt; mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><b><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>The Potential Market: The market for Type II Diabetes drug worldwide is estimated to be more than $10 billion annually. </span></b><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt; font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>Biotech’s first goal is to bring DIAB II onto the market in Latin America, as preparation for bringing DIAB II to the drug market in the U.S. and Canada. <b>Discussions with potential pharmaceutical partners for the U.S. market have begun.</b> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>In Latin America, Mexico is first on the company’s list of target markets. In his report to shareholders issued March 1, 2002, the President of Biotech Holdings, Robert Rieveley, said: <b>We believe that we are well positioned for receiving regulatory approval shortly.<span style="mso-spacerun: yes"> </span>Accordingly, we have been making preparations for supply of DIAB II to the Mexican market, which is the eighth largest pharmaceutical market in the world. </b></span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>In Latin America, DIAB II has already been approved in Peru and Biotech has signed distribution agreements for <b>Venezuela, Chile and Argentina</b>.<span style="mso-spacerun: yes"> </span>In other markets, a distributor has been signed for <b>Turkey</b> and preliminary agreements are in place for <b>Spain, Greece, South Africa</b> and several markets in the Middle East and South Asia. </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>The <b>U.S. patents that protect DIAB II</b> - - issued on November 28, 2000 and September 18, 2001 - - confer the sole right to the use of treatments combining insulin-sensitizing drugs with any other standard medications for Type II Diabetes.<span style="mso-spacerun: yes"> </span><b>Many large pharmaceutical companies active in the diabetes field may be affected. </b></span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>In addition to its prescription drug business, Biotech has a non-prescription, personal care products division which is showing steady growth.<span style="mso-spacerun: yes"> </span>In addition to its growing private label business, this division is planning to launch a new line of high-margin cosmetic products, which will be sold primarily in the U.S.</span><span style='font-size:9.0pt;mso-bidi-font-size: 12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'> </span><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Arial'><o:p></o:p></span></p> <p class=MsoNormal style='text-align:justify'><span style='font-size:9.0pt; mso-bidi-font-size:10.0pt;font-family:Arial'>Biotech’s revenues are set to grow sharply as <b>markets for DIAB II open up</b>, as <b>non-prescription revenues grow</b> and as the implications of the above-mentioned patents are pursued, <b>with potential for royalty payments from major pharmaceutical companies</b>. In his Report to Shareholders, the President of Biotech concluded: <b>We look forward with enthusiasm to developments in the coming months.</b><b style='mso-bidi-font-weight:normal'> <o:p></o:p></b></span></p> <h1 align=left style='text-align:left'> <span style='font-family:"Calisto MT"'><o:p></o:p></span></h1> </td> <td width=327 valign=top style='width:245.2pt;padding:0in 5.4pt 0in 5.4pt; height:620.5pt'> <table border=0 cellspacing=0 cellpadding=0 align=left width=323 style='width:242.6pt;border-collapse:collapse;border:none;mso-border-alt: solid windowtext .5pt;mso-table-overlap:never;mso-table-lspace:9.0pt; mso-table-rspace:9.0pt;mso-table-anchor-vertical:paragraph;mso-table-anchor-horizontal: margin;mso-table-left:left;mso-table-top:97.8pt;mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr> <td width=179 valign=top style='width:134.6pt;border:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:white'>Company Name<o:p></o:p></span></p> </td> <td width=144 valign=top style='width:1.5in;border:solid windowtext .5pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;background:#E5D68D; padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial'>Biotech Holdings Ltd.<o:p></o:p></span></b></p> </td> </tr> <tr> <td width=179 valign=top style='width:134.6pt;border:solid windowtext .5pt; border-top:none;background:green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:white'>Stock Exchange in U.S<o:p></o:p></span></p> </td> <td width=144 valign=top style='width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:black'>OTC BB: BIOHF</span><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial'><o:p></o:p></span></p> </td> </tr> <tr> <td width=179 valign=top style='width:134.6pt;border:solid windowtext .5pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;background:green; padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:white'>Stock Exchange in Canada<o:p></o:p></span></p> </td> <td width=144 valign=top style='width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:black'>TSX.Venture: BIO</span><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial'><o:p></o:p></span></p> </td> </tr> <tr> <td width=179 valign=top style='width:134.6pt;border:solid windowtext .5pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;background:green; padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:white'>52-week High/Low BIOHF<o:p></o:p></span></p> </td> <td width=144 valign=top style='width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:black'>$.26/$0.05</span><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial'><o:p></o:p></span></p> </td> </tr> <tr> <td width=179 valign=top style='width:134.6pt;border:solid windowtext .5pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;background:green; padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:white'>52-week High/Low BIO<o:p></o:p></span></p> </td> <td width=144 valign=top style='width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><span style='font-size:10.0pt;font-family:"Calisto MT"; mso-bidi-font-family:Arial;color:black'>$.42/$.07</span><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial'><o:p></o:p></span></p> </td> </tr> </table> <p class=MsoNormal> </p> <p class=MsoNormal> </p> <p class=MsoNormal> </p> <p class=MsoHeader style='tab-stops:.5in center 3.0in right 6.0in'> </p> <p class=MsoNormal> </p> <p class=MsoNormal> </p> <table border=0 cellspacing=0 cellpadding=0 bgcolor="#e5d68d" style='background:#E5D68D;border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr> <td width=324 valign=top style='width:242.65pt;padding:0in 5.4pt 0in 5.4pt'> <h1 align=left style='text-align:left;tab-stops:12.75pt center 115.9pt'><span style='font-family:"Calisto MT";color:green'><span style='mso-tab-count: 2'> </span>THE OPPORTUNITY<o:p></o:p></span></h1> </td> </tr> </table> <p><b><i><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family: Arial;color:black'>"Revenues for the 10-week period from March 1, 2002 to May 10, 2002 were $579,148. This represents 42% growth over revenue for the year-earlier 13-week period from March 1, 2001 through May 31, 2001," Mr. Rieveley said. </span></i></b><b><i><span style='font-size: 9.0pt;mso-bidi-font-size:12.0pt;color:black'><o:p></o:p></span></i></b></p> <p><b><i><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family: Arial;color:black'>"In the current quarter, we are looking for continuing improvement in our year-over-year revenue numbers," Mr. Rieveley added. </span></i></b><b><i><span style='font-size:9.0pt;mso-bidi-font-size: 12.0pt;color:black'><o:p></o:p></span></i></b></p> <p><b><i><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family: Arial;color:black'>"I am also pleased to announce that we are moving towards initiating production of a new, high-margin line of skin, hair and cosmetic products which is planned to be widely sold in North America," Mr. Rievely said. "Our Biotech Laboratories plant will produce a significant portion of the products required by this new distribution channel. We expect this additional production, targeted to begin in August, 2002, to have a significant impact on both total revenues and on profit margins for Biotech Holdings."</span></i></b><span style='font-family:Arial; color:#000066'> </span></p> <p class=MsoNormal><![if !supportEmptyParas]> <![endif]><o:p></o:p></p> <table border=0 cellspacing=0 cellpadding=0 bgcolor="#e5d68d" style='background:#E5D68D;border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr> <td width=324 valign=top style='width:242.65pt;padding:0in 5.4pt 0in 5.4pt'> <h2 align=center style='text-align:center'><span style='font-family:"Calisto MT"; color:green'>INVESTOR INFORMATION</span><span style='color:green'><o:p></o:p></span></h2> </td> </tr> </table> <p class=MsoNormal><b><span style='font-family:"Calisto MT";color:black'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></b></p> <table border=0 cellspacing=0 cellpadding=0 width=332 style='width:249.0pt; border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>Active Float:</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>20,000,000</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>U.S. SEC Registration No.:</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>0 - 29108</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>Shares outstandingMar.31/02:</span><span style='font-size: 10.0pt;mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>69,928,130</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>Recent Market Cap:</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>$6,300,000 US</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>Stock Exchange in U.S.:</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>OTC BB: BIOHF</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>Stock Exchange in Canada: </span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>TSX.Venture:BIO</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt'><o:p></o:p></span></p> </td> </tr> <tr> <td width=192 valign=top style='width:144.2pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: green;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>52-week High/Low BIOHF:</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;border-bottom: solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;background: #E5D68D;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>$.26/$0.05</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> <tr style='height:3.5pt'> <td width=192 valign=top style='width:144.2pt;border:none;mso-border-top-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:white'>52-week High/Low BIO:</span><span style='font-size:10.0pt; mso-bidi-font-size:12.0pt;color:white'><o:p></o:p></span></p> </td> <td width=140 valign=top style='width:104.8pt;border:none;mso-border-top-alt: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'> <p class=MsoNormal align=center style='text-align:center'><span style='font-size:10.0pt;font-family:"Calisto MT";mso-bidi-font-family:Arial; color:black'>$.42/$.07</span><span style='font-size:10.0pt;mso-bidi-font-size: 12.0pt'><o:p></o:p></span></p> </td> </tr> </table> <p class=MsoNormal align=center style='text-align:center'><b><span style='font-family:"Calisto MT";color:black'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></b></p> <p class=MsoNormal style='tab-stops:15.0pt center 124.85pt'><b><span style='font-family:"Calisto MT";color:black'><span style='mso-tab-count:2'> </span><a href="http://www.biotechltd.com/">www.biotechltd.com</a><o:p></o:p></span></b></p>; <p class=MsoNormal align=center style='text-align:center'> </p> </td> </tr> </table> <p class=MsoBodyText2 style='text-align:justify'><span lang=EN-CA style='mso-ansi-language:EN-CA'>The Investment Journal: The information herein has been obtained from sources which are believed to be reliable, but there are no guarantees as to its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Biotech Holdings has not paid any cash or shares for its appearance on this report.<span style="mso-spacerun: yes"> </span>Some or all employees at The Investment Journal may hold shares in companies featured. We do not recommend or constitute "buy" or "sell" signals or advisories for our readers. The Investment Journal is not a securities broker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange Commission nor any state securities regulation authority. Consult with your financial advisor before making any financial decisions.<o:p></o:p></span></p> <p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight: normal'><span lang=EN-CA style='font-size:7.5pt;mso-ansi-language:EN-CA'>This Newsletter is intended for our opt-in readers only. If you have received this email in error, </span></b><b style='mso-bidi-font-weight:normal'><span lang=EN-CA style='font-size:7.5pt;mso-bidi-font-size:12.0pt;mso-ansi-language: EN-CA'>you may remove your address by </span></b><b style='mso-bidi-font-weight: normal'><span lang=EN-CA style='font-size:7.5pt;mso-ansi-language:EN-CA'>e-mailing</span></b><b style='mso-bidi-font-weight:normal'><span lang=EN-CA style='font-size:9.0pt; mso-bidi-font-size:12.0pt;font-family:Arial;mso-ansi-language:EN-CA'> <o:p></o:p></span></b></p> <p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight: normal'><span lang=EN-CA style='font-size:8.0pt;mso-bidi-font-size:12.0pt; mso-ansi-language:EN-CA'><a href="mailto:the-journal@excite.com?subject=Remove">the-journal@excite.com</a></span></b><b><span lang=EN-CA style='font-size:36.0pt;mso-bidi-font-size:12.0pt;font-family:Algerian; color:green;mso-ansi-language:EN-CA'><o:p></o:p></span></b></p> </div> </body> </html> N…'²æìr¸›zǧvf¢–Ú&j:+v‰¨·ž è® "¶§²æìr¸›yúÞy» ªç¬¶*'²)í…æèw* ¶¦zËhome | help
Want to link to this message? Use this
URL: <https://mail-archive.FreeBSD.org/cgi/mid.cgi?52F8B3D6.000000013.4A3B.9B83.C9C33FE204B7>